Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLKB1 known ✓ | P03952 | 1/20 | 0.33 |
| ▸ | GAA known ✓ | P10253 | 2/20 | 0.33 |
| ▸ | IRAK4 | Q9NWZ3 | 7/20 | 0.34 |
| ▸ | ACACB | O00763 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL8932295 | 1.00 | IRAK4 (0.34) | IRAK4ACACBMEN1KMT2ACYP11B1 | |
| SCHEMBL20141 | 0.98 | IRAK4 (0.35) | IRAK4ACACBMEN1KMT2ACYP11B1 | |
| SCHEMBL28726067 | 0.96 | IRAK4 (0.35) | IRAK4ACACBMEN1KMT2ACYP11B1 | |
| SCHEMBL8932291 | 0.90 | CYP11B1 (0.33) | IRAK4ACACBMEN1KMT2ACYP11B1 | |
| SCHEMBL31265253 | 0.86 | MEN1 (0.32) | ACACBMEN1KMT2AKLKB1 | |
| SCHEMBL460661 | 0.84 | LMNA (0.34) | GAALMNAPOLB | |
| Hydrochloric Acid SCHEMBL31096988 | 0.84 | ADORA2A (0.36) | IRAK4ACACBCYP11B1CYP11B2KLKB1 | |
| Hydrochloric Acid SCHEMBL38654637 | 0.84 | KLKB1 (0.34) | IRAK4ACACBCYP11B1CYP11B2KLKB1 | |
| SCHEMBL14010542 | 0.84 | LMNA (0.35) | IRAK4ACACBKMT2ACYP11B1CYP11B2 | |
| SCHEMBL345169 | 0.82 | ADORA2A (0.37) | IRAK4ACACBCYP11B1CYP11B2KLKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114957123-B | 3- (difluoromethyl) -pyrazole-4-carboxylic ester derivative and preparation method and application thereof | 浙江工业大学 | 2023-11-28 | — | — | CN | claimed |
| CN-119735548-A | Improved process for preparing biphenylamide compounds | 兰升生物科技集团股份有限公司 | 2025-04-01 | — | — | CN | disclosed |
| CN-119431246-A | Bispyrimidine marked with dichloro benzene ring carbon-14 and preparation method thereof | 浙江爱索拓科技有限公司 | 2025-02-14 | — | — | CN | disclosed |
| CN-119285548-A | Fluoconazole fungus Process for the preparation of amides | 湖南化工研究院有限公司 | 2025-01-10 | — | — | CN | disclosed |
| CN-115836041-B | Process for producing optically active compound | 住友化学株式会社 | 2024-09-17 | — | — | CN | disclosed |
| US-20230257408-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2023-08-17 | — | — | US | disclosed |
| EP-4186882-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2023-05-31 | — | — | EP | disclosed |
| US-11234439-B2 | Imide compound and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2022-02-01 | — | — | US | disclosed |
| CN-109661388-B | Imide compound and use thereof | 住友化学株式会社 | 2021-11-26 | — | — | CN | disclosed |
| US-20210274786-A1 | IMIDE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2021-09-09 | — | — | US | disclosed |
| US-8273783-B2 | Microbiocides | SYNGENTA CROP PROTECTION LLC (US) | 2012-09-25 | — | — | US | disclosed |
| US-8268877-B2 | Microbiocides | SYNGENTA CROP PROTECTION, LLC (US) | 2012-09-18 | — | — | US | disclosed |
| WO-2012113696-A1 | NOVEL CARBOXAMIDE MICROBIOCIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2012-08-30 | — | — | WO | disclosed |
| EP-2451799-A1 | NOVEL MICROBIOCIDES | Syngenta Participations AG (CH) | 2012-05-16 | — | — | EP | disclosed |
| US-20120108645-A1 | NOVEL MICROBIOCIDES | SYNGENTA CROP PROTECTION LLC (US) | 2012-05-03 | — | — | US | disclosed |
| US-20110281924-A1 | NOVEL MICROBIOCIDES | SYNGENTA CROP PROTECTION LLC (US) | 2011-11-17 | — | — | US | disclosed |
| EP-2379536-A1 | NOVEL MICROBIOCIDES | Syngenta Participations AG (CH) | 2011-10-26 | — | — | EP | disclosed |
| WO-2011003683-A1 | NOVEL MICROBIOCIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2011-01-13 | — | — | WO | disclosed |
| WO-2010084078-A1 | NOVEL MICROBIOCIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2010-07-29 | — | — | WO | disclosed |
| US-5498624-A | PLANT FUNGICIDES | MONSANTO COMPANY (US) | 1996-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110281924-A1 | NOVEL MICROBIOCIDES | CD14, FPR1, MPO | KLKB1 946/4885GAA 1343/4885IRAK4 1321/4885 |
| US-20230257408-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUND | SIRT1, SIRT3, HCCS | KLKB1 4685/4885GAA 2814/4885IRAK4 3536/4885 |
| US-20210274786-A1 | IMIDE COMPOUND AND USE THEREOF | RAB29, RIN1, RICTOR | KLKB1 4867/4885GAA 1115/4885IRAK4 1060/4885 |
| US-20120108645-A1 | NOVEL MICROBIOCIDES | FPR1, CD14, MPO | KLKB1 1126/4885GAA 1489/4885IRAK4 1330/4885 |
| US-11234439-B2 | Imide compound and use thereof | RAB29, RIN1, RICTOR | KLKB1 4867/4885GAA 1115/4885IRAK4 1060/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.